Neuroscientific Biopharmaceuticals (ASX:NSB)
ASX announcement history & article coverage
Transparent by design.
Announcments by Neuroscientific Biopharmaceuticals (ASX:NSB) are listed here, whether we covered it or not. Where we've written an article, you'll see it linked directly. Where we haven't, the filing is still shown so nothing is hidden from view. If you think a particular announcement deserved editorial coverage and was overlooked, you can flag it for review and our team will take a look.
Resignation and Appointment of Auditor
Appendix 4G & Corporate Governance Statement
2026 Annual Report & Appendix 4E
NeuroScientific reports $4.69M loss, advances StemSmart clinical program, ceases EmtinB development
Pre-IND Meeting with US FDA Scheduled
NSB schedules Pre-IND meeting with US FDA for Phase 2 trial of StemSmart in refractory Crohn's disease
Quarterly Activities/Appendix 4C Cash Flow Report
NeuroScientific reports positive clinical results for StemSmart™ in Crohn's disease and advances Phase 2 trial planning
StemSmart Presentation - ISCT ANZ 2026
Notification of cessation of securities - NSB
Escrowed Securities Update
Investor Webinar
Change in substantial holding